Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 2/20 | 0.44 |
| ▸ | GPR6 | P46095 | 3/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.39 |
| ▸ | PRKCZ | Q05513 | 5/20 | 0.39 |
| ▸ | PRKD2 | Q9BZL6 | 4/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | MLNR | O43193 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2426257 | 0.93 | IRAK4 (0.43) | ROCK2GPR6KDM1AMAOAMAOB | |
| SCHEMBL13087807 | 0.93 | IRAK4 (0.43) | ROCK2GPR6KDM1AMAOAMAOB | |
| SCHEMBL13087709 | 0.92 | ROCK2 (0.44) | ROCK2GPR6KDM1AMAOAMAOB | |
| SCHEMBL13087318 | 0.92 | CYP11B1 (0.44) | ROCK2GPR6KDM1AMAOAMAOB | |
| SCHEMBL13087530 | 0.92 | IRAK4 (0.45) | ROCK2GPR6KDM1AMAOAMAOB | |
| SCHEMBL13087870 | 0.91 | ROCK2 (0.42) | ROCK2GPR6KDM1AMAOAMAOB | |
| SCHEMBL12327356 | 0.90 | CPT1A (0.45) | ROCK2GPR6SYKDGAT2 | |
| SCHEMBL2428040 | 0.90 | ROCK2 (0.43) | ROCK2GPR6DGAT2PRKCZPRKD2 | |
| SCHEMBL2425647 | 0.90 | ROCK2 (0.43) | ROCK2GPR6PRKCZPRKD2SLC6A7 | |
| SCHEMBL2426924 | 0.90 | PAX8 (0.44) | ROCK2GPR6DGAT2PRKCZPRKD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299055-B2 | 8-substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-10-30 | — | — | US | disclosed |
| US-8299055-B2 | 8-substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | RELA, NFKBIA, NFKB2 | ROCK2 1065/4885GPR6 2528/4885KDM1A 1279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.